Skip to main content

Advertisement

SpringerLink
Log in

Assessment of renal and skeletal components of hypercalcemia

  • Symposium Proceedings
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

The management of hypercalcemia of malignancy is guided by assessments of its various components. Since the intestine usually makes no contribution to hypercalcemia under these circumstances, the problem is to measure the net efflux of calcium out of bone and the ability of the kidneys to excrete the unwanted calcium load. Established relationships between serum and urinary calcium excretion rates allow the quantitation of the relative contribution of an impaired glomerular filtration rate, of reduced renal tubular calcium reabsorption, and of increased bone resorption. Since the renal handling of calcium is closely related to that of sodium in the proximal nephron, the rate of sodium excretion is an important variable in these measurements. A practical approach to the separation of hypercalcemia into its renal and skeletal components is described in this article. Examples of how these measurements can be used to assess the responses to various types of therapy for malignancy-associated hypercalcemia are also given.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grossman B, Schechter GP, Horton JE, Pierce L, Jaffe E, Wahl L. Hypercalcemia associated with T cell lymphomaleukemia.Am J Clin Pathol 1981;75:149–155.

    PubMed  CAS  Google Scholar 

  2. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CYC. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma.Ann Intern Med 1984;100:1–7

    PubMed  CAS  Google Scholar 

  3. Mundy GR. Hypercalcemia of malignancy revisited.J Clin Invest 1988;82:1–6

    Article  PubMed  CAS  Google Scholar 

  4. Benable JE, Martinez-Maldonado M. Hypercalcemic nephropathy.Arch Intern Med 1978;138:777–779

    Article  Google Scholar 

  5. Agus S. Renal tubular transport of calcium: update.Adv Exp Med Biol 1978;103:37–49

    PubMed  CAS  Google Scholar 

  6. Suki WN. Calcium transport in the nephron.Am J Physiol 1979;237:F1-F6

    PubMed  CAS  Google Scholar 

  7. Rizzoli R, Caverzasio J, Fleisch H, Bonjour JP. Parathyroid hormone-like changes in renal calcium and phosphate reabsorption induced by Leydig cell tumor in thyroparathyroidectomized rats.Endocrinology 1986;119:1004–1009

    Article  PubMed  CAS  Google Scholar 

  8. Broadus AE, Mangin M, Ikeda K, Isogna KL, Weir EC, Burtis WJ, Stewart AF. Humoral hypercalcemia of cancer: identification of a novel parathyroid hormone-like peptide.N Engl J Med 1988;319:556–563

    Article  PubMed  CAS  Google Scholar 

  9. Dousa TP, Valtin H. Cellular actions of vasopressin in the mammalian kidney.Kidney Int 1976;10:40–63

    Google Scholar 

  10. Parfitt M. Equilibrium and disequilibrium hypercalcemia: new light on an old concept.Metab Bone Dis Relat Res 1979;1:279–293

    Article  Google Scholar 

  11. Nordin BEC. Plasma calcium and magnesium homeostasis. In Nordin BEC (ed).Calcium, Phosphate and Magnesium Metabolism. Edinburgh, Churchill Livingston, 1976; pp. 186–216

    Google Scholar 

  12. Peacock M, Robertson WG, Nordin BEC. Relation between serum and urinary calcium with particular reference to parathyroid activity.Lancet 1969;i:384–386

    Article  Google Scholar 

  13. Hosking DJ, Cowley AJ, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia.Q J Med 1981;50:473–481

    PubMed  CAS  Google Scholar 

  14. Hosking DJ, Gilson D. Comparison of the renal skeletal action of calcitonin in the treatment of severe hypercalcaemia of malignancy.Q J Med 1984;53:359–368

    PubMed  CAS  Google Scholar 

  15. Heller SR, Hosking DJ. Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.Br Med J 1986;292:583–586

    Article  CAS  Google Scholar 

  16. Hosking DJ, Heller SR. Quantitation of the renal effect of calcitonin in the hypercalcaemia of malignancy.Eur J Clin Pharmacol 1986;31:27–31

    Article  PubMed  CAS  Google Scholar 

  17. Wener JA, Gorton SJ, Raisz LG. Escape from inhibition of resorption in cultures of fetal bone treated with calcitonin and parathyroid hormone.Endocrinology 1972;90:752–759

    PubMed  CAS  Google Scholar 

  18. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy.Ann Intern Med 1980;93:269–272

    PubMed  CAS  Google Scholar 

  19. Hosking DJ, Stone MD, Foote JW. Potentiation of calcitonin by corticosteroids during treatment of the hypercalcaemia of malignancy.Eur J Clin Pharmacol (in press)

Download references

Author information

Authors and Affiliations

  1. Metabolism/Diabetes, City Hospital, Hucknall Road, NG5 1PB, Nottingham, UK

    David J. Hosking

Authors
  1. David J. Hosking
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hosking, D.J. Assessment of renal and skeletal components of hypercalcemia. Calcif Tissue Int 46 (Suppl 1), S11–S19 (1990). https://doi.org/10.1007/BF02553288

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02553288

Keywords

Search

Navigation